Nebraska Medicaid spending on GLP-1 drugs

How much did Nebraska Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $36.1 million for GLP-1 drugs paid through Nebraska Medicaid in 2025, across at least 37,335 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 48 rows of 144, so these figures are floors.

Pharmacies were reimbursed at least $9.4 million for GLP-1 drugs paid through Nebraska Medicaid in 2026 (quarter 1 only, as posted so far), across at least 9,278 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 14 rows of 41, so these figures are floors.

By year and ingredient

2020at least $331,845No dataat least $1,916,940at least $536,823at least $1,468,422at least $9,596Suppressedat least $4,263,626
2021at least $1,033,110No dataat least $4,193,745at least $2,783,478at least $1,233,703at least $25,272at least $9,156at least $9,278,463
2022at least $2,921,603at least $70,516$3,568,268at least $11,179,691at least $485,686$77,835Suppressedat least $18,303,599
2023at least $11,900,957at least $1,455,043$2,266,293at least $13,302,508at least $215,937$50,620Suppressedat least $29,191,359
2024at least $19,395,149at least $3,188,672at least $761,886at least $8,386,370at least $86,805at least $29,075Suppressedat least $31,847,957
2025at least $23,329,922at least $5,989,103at least $162,191at least $6,614,063at least $14,875at least $7,267Suppressedat least $36,117,422
2026 (Q1)at least $5,793,409at least $2,183,249at least $23,474$1,426,074No dataSuppressedNo dataat least $9,426,206

By product, 2025

Ozempicat least $22,756,604at least 23,5782 of 14
Rybelsus$421,9984620 of 12
Wegovyat least $151,320at least 11612 of 20
Mounjaro$5,613,8945,6860 of 24
Zepboundat least $375,208at least 35510 of 18
Liraglutide (generic name listing)at least $40,889at least 10017 of 23
Victoza$121,3021990 of 8
Trulicityat least $6,614,063at least 6,8091 of 17
Bydureonat least $14,875at least 191 of 2
Soliquaat least $7,267at least 113 of 4
XultophySuppressedSuppressed2 of 2

By quarter, 2025

Q1 2025at least $8,387,152at least 8,86112 of 34
Q2 2025at least $8,935,940at least 9,28413 of 36
Q3 2025at least $9,311,501at least 9,55611 of 36
Q4 2025at least $9,482,829at least 9,63412 of 38

By quarter, 2026 (posted so far)

Q1 2026at least $9,426,206at least 9,27814 of 41

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.